Crossref
26-A-9768-ACC REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY
JACC · 2026-04 · 87 (13) · A170-A171
DOI: 10.1016/j.jacc.2026.02.425 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Byung Gyu Kim und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kim, B. G., & Park, S. (2026). 26-A-9768-ACC REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY. JACC, 87(13), A170-A171. https://doi.org/10.1016/j.jacc.2026.02.425
Vancouver
Kim BG, Park S. 26-A-9768-ACC REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY. JACC. 2026;87(13):A170-A171. doi:10.1016/j.jacc.2026.02.425
BibTeX
@article{Kim2026,
author = {Kim, Byung Gyu and Park, Seong-Mi},
title = {26-A-9768-ACC REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A170--A171},
doi = {10.1016/j.jacc.2026.02.425}
}
EUVIMED